Read Time:7 Second
Analysts said upcoming data on Pfizer’s obesity pill, danuglipron, will be crucial to how competitive the company can be against Eli Lilly and Novo Nordisk.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
